{"id":"piroheptine","rwe":[{"pmid":"2236897","year":"1990","title":"Effects of anticholinergic antiparkinsonian drugs on binding of muscarinic receptor subtypes in rat brain.","finding":"","journal":"Research communications in chemical pathology and pharmacology","studyType":"Clinical Study"},{"pmid":"1975759","year":"1990","title":"Biperiden and piroheptine do not affect the serum level of zotepine, a new antipsychotic drug.","finding":"","journal":"The British journal of psychiatry : the journal of mental science","studyType":"Clinical Study"},{"pmid":"3258627","year":"1988","title":"Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl.","finding":"","journal":"Journal of the neurological sciences","studyType":"Clinical Study"},{"pmid":"5068358","year":"1972","title":"Effect of piroheptine, a new antiparkinson drug, on dopamine uptake into synaptosomes from corpus striatum of rat brain.","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"},{"pmid":"4626187","year":"1972","title":"Pharmacological study of piroheptine, a new antiparkinson drug, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-ethyl-2-methylpyrrolidine. I. Effects on drug-induced tremor and catatonia, and on adrenergic actions.","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"}],"tags":[{"label":"piroheptine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["piroheptine hydrochloride","piroheptine","piroheptine HCl"],"offLabel":[],"synonyms":["piroheptine hydrochloride","piroheptine","piroheptine HCl"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"piroheptine","explanation":"Imagine your body's cells have locks on them, and piroheptine is a key that fits into one of those locks. When it binds to the lock, it can either block or enhance the activity of the cell, depending on the specific lock and key interaction. This can help to either reduce or increase the activity of certain cellular processes.","oneSentence":"Piroheptine is a small molecule that works by interacting with a specific target in the body.","technicalDetail":"Piroheptine's exact mechanism of action is unknown, but it is believed to interact with a specific receptor or enzyme in the body, potentially modulating its activity through allosteric or competitive binding."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2208","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PIROHEPTINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:21:26.512276","biosimilars":[],"competitors":[],"genericName":"piroheptine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"008199","UNII":"AR6Y753ARL","CHEBI":"CHEBI:135287","INN_ID":"3069","UMLSCUI":"C0071147","ChEMBL_ID":"CHEMBL2106830","KEGG_DRUG":"D01231","PUBCHEM_CID":"4854","SECONDARY_CAS_RN":"16378-22-6","MESH_SUPPLEMENTAL_RECORD_UI":"C055566"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":6,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1990 Sep","pmid":"2236897","title":"Effects of anticholinergic antiparkinsonian drugs on binding of muscarinic receptor subtypes in rat brain.","journal":"Research communications in chemical pathology and pharmacology"},{"date":"1990 Jul","pmid":"1975759","title":"Biperiden and piroheptine do not affect the serum level of zotepine, a new antipsychotic drug.","journal":"The British journal of psychiatry : the journal of mental science"},{"date":"1988 Feb","pmid":"3258627","title":"Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl.","journal":"Journal of the neurological sciences"},{"date":"1972 Jun","pmid":"5068358","title":"Effect of piroheptine, a new antiparkinson drug, on dopamine uptake into synaptosomes from corpus striatum of rat brain.","journal":"Arzneimittel-Forschung"},{"date":"1972 Jun","pmid":"4626187","title":"Pharmacological study of piroheptine, a new antiparkinson drug, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-ethyl-2-methylpyrrolidine. I. Effects on drug-induced tremor and catatonia, and on adrenergic actions.","journal":"Arzneimittel-Forschung"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"PIROHEPTINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Piroheptine is a small molecule drug in the piroheptine class, but specific details about its development, ownership, and commercial status are not available. Its target and mechanism of action are also unknown. Piroheptine's approved indications, half-life, bioavailability, and generic manufacturers are not specified. As a result, its commercial status and key safety considerations cannot be accurately assessed. Further research is necessary to understand the pharmacology and clinical utility of piroheptine.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}